Litcius/Paper detail

LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli, Austin Miller, Charles Anderson, Giovanni Scambia, Tashanna Myers, Çağatay Taşkıran, Katina Robison, Johanna Mäenpää, Lyndsay Willmott, Nicoletta Colombo, Jessica Thomes-Pepin, Michael A. Gold, Carol Aghajanian, Fan Wu, Luciana Molinero, Victor K. Khor, Yufen Lin, Sandro Pignata

2020Annals of Oncology36 citationsDOI

Topics & Concepts

MedicineAtezolizumabBevacizumabInternal medicineClinical endpointPopulationOncologyCarboplatinPhases of clinical researchChemotherapyGastroenterologySurgeryUrologyClinical trialCancerCisplatinImmunotherapyPembrolizumabEnvironmental healthOvarian cancer diagnosis and treatmentCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments
LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC) | Litcius